ClinicalTrials.gg
CompletedNCT0564189618F-FAPI-74 GIUpdated Oct 1, 2026Results posted

Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

A Phase 2 interventional study of [18F]FAPI-74 PET/CT in Gastrointestinal Cancers, Cholangiocarcinoma and Gastric Cancer, sponsored by SOFIE. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by SOFIE · Phase 2, Interventional, and Diagnostic

Updated Oct 1, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.

Enrollment
82nd of 245
112 · median 60
Started
2023
with 24 others
Phase 2
42 of 316
8 open now
Registered
237th of 316
by date

Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 82nd largest by enrollment of the 245 interventional ones that give a count, is one of 25 that started in 2023, is one of 42 in phase 2, and was the 237th registered.

Gastrointestinal Neoplasms

696 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 122 (76%) set no upper age limit and 18 (11%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Gastrointestinal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer. The [18F]FAPI-74 PET scan will be acquired in patients with proven GI cancers after initial staging using institutional standard methods. The PET scan results will be compared to FAP immunohistochemistry (as the primary objective) and histopathology (as the secondary objective) of the biopsied or resected tissues.

03

Conditions studied

  • Gastrointestinal Cancers
  • Cholangiocarcinoma
  • Gastric Cancer
  • Colorectal Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Hepatocellular Carcinoma

Keywords

  • Fibroblast Activation Protein
  • Fibroblast Activation Protein Inhibitor
  • FAPI
  • Gastrointestinal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of gastrointestinal (GI) , including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer
  • Available tissue sample obtained through or to be obtained through scheduled biopsy and/or surgical resection
  • No treatment received between tissue sample taken and [18F]FAPI-74 PET
  • Anatomic imaging (e.g., CT, MRI) obtained within ≤ 28 days of consent
  • Age ≥ 18 years
  • Completed as determined per the IRB of record

Exclusion criteria

Exclusion Criteria:

  • Pregnant as determined by a pregnancy test as per institutional guidelines for individuals of
  • Declining to use effective methods during the study (for individuals of child-producing potential)
  • Need for emergent surgery that would be delayed by participation
  • Bacterial, viral, or fungal infections requiring systemic therapy, that are expected to impact FAP expression in the opinion of the sponsor or their designee
  • Serious co-morbidities and serious nonmalignant disease (e.g., hydronephrosis, kidney failure, liver failure, systemic or local inflammatory or diseases or other conditions) that in the opinion of the investigator, physician of record and/or Sofie could compromise subject safety and/or protocol objectives
  • Known diagnosis of an autoimmune disorder that is expected to impact FAP expression in the opinion of the sponsor or their designee
  • Patients receiving any other agent within the past 28 days
  • Breastfeeding. Note: nursing parents are allowed if the potential participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the [18F]FAPI-74 injection
  • Known to any used in [18F]FAPI-74: trace amounts of sodium acetate, sodium ascorbate, ascorbic acid, ethanol, acetonitrile or AlCl.
  • Renal or liver function impairment* *Defined by liver impairments as >3x the , ALT>3x the upper limit of normal, or >1.5x the upper limit of normal. Renal impairment as defined by a of >1.5x the upper limit of normal utilizing the Cockcroft Gault formula
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    [18F]FAPI-74 PET/CT

    Patients receive \[18F\]FAPI-74 intravenously followed by PET/CT 60 minutes (+/-10minutes) later

    Drug: [18F]FAPI-74 PET/CT

Interventions

  • Drug[18F]FAPI-74 PET/CT

    Drug page: Fluorine F 18 FAPI-74

    \[18F\]FAPI-74 is a radioactive diagnostic agent indicated for use with Positron Emission Tomography (PET) imaging for the detection of Fibroblast Activation Protein (FAP) positive cancer cells and cancer-associated fibroblasts (CAF) in patients with gastrointestinal cancers.

06

What researchers measure

Primary outcomes

  1. Positive Predictive Value (PPV) of [18F]FAPI-74 PET Imaging Using Immunohistochemistry (IHC)

    The positive or negative status according to \[18F\]FAPI-74 PET imaging was determined based on a prespecified cut-off value for each appropriate test as determined by the clinician. Positivity was evaluated using the following prespecified H-score thresholds: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only. The primary efficacy endpoint was the positive predictive value of \[18F\]FAPI-74 PET imaging, defined as the proportion of PET-positive results that were confirmed positive by IHC. PPV was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.

    Time frame: Day 1

  2. Sensitivity of [18F]FAPI-74 PET Imaging to Detect FAP-Expressing Cells, Using IHC

    Sensitivity was defined as the proportion of participants with IHC confirmed FAP-expressing cells who had a positive \[18F\]FAPI-74 PET result for the primary lesion. Sensitivity was calculated as A / (A + C), where A represents true positive findings and C represents false negative findings. Higher sensitivity indicates a greater ability of \[18F\]FAPI-74 PET to detect IHC confirmed FAP expression and a lower likelihood of false negative results, thereby reflecting the effectiveness of the imaging modality relative to the IHC reference standard. Sensitivity was presented overall for all IHC-positive results and separately using stricter IHC cut-off values categorized as: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.

    Time frame: Day 1

  3. Specificity of [18F]FAPI-74 PET Imaging to Detect Absence of FAP-Expressing Cells, Using IHC as Truth Standard

    Specificity was defined as the proportion of participants without IHC-confirmed FAP-expressing cells who had a negative \[18F\]FAPI-74 PET result for the primary lesion. Specificity was calculated by comparing positive and negative \[18F\]FAPI-74 PET findings with the corresponding IHC results, using a single readable PET image matched to its reference IHC assessment. Specificity was calculated as D / (B + D), where B represents false-positive findings and D represents true-negative findings. PET results were compared with the corresponding IHC reference assessment using a single readable PET image per participant. Specificity was evaluated overall using IHC negativity defined as \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.

    Time frame: Day 1

Secondary outcomes

  1. PPV of [18F]FAPI-74 PET Images to Detect Cancer Cells Using Histopathology as Truth Standard

    Positive Predictive Value (PPV) of \[18F\]FAPI-74 PET imaging in detecting presence of disease using histopathology as the truth standard. The PPV is defined as the probability that one is indeed positive for an outcome given that they test positive for the outcome and is calculated as: PPV = A/(A + B), where A represents true-positive findings and B represents false-positive findings (PET positive but histopathology negative). PPV was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.

    Time frame: Day 1

  2. Sensitivity of [18F]FAPI-74 PET Imaging to Detect Cancers Cells, Using Histopathology as Truth Standard

    Sensitivity was defined as the proportion of participants with histopathology-confirmed cancers cells who had a positive \[18F\]FAPI-74 PET result for the primary lesion. Sensitivity was calculated by comparing positive and negative \[18F\]FAPI-74 PET findings with the corresponding histopathology results, using a single readable PET image matched to its reference histopathology assessment. Sensitivity was calculated as A / (A + C), where A represents true-positive findings and C represents false-negative findings. Sensitivity was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.

    Time frame: Day 1

  3. Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) is any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the trial intervention. A TEAE is defined as any untoward medical occurrence that begins or worsens in intensity or frequency after the initiation of a treatment (e.g., drug, device, or procedure) in a clinical study. A serious TEAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization.

    Time frame: From study intervention administration (Day 1) to 72 hours post-injection

07

Results

Posted Oct 1, 2026

Participant flow

This was a Phase 2, prospective, non-randomized, open-label, multicenter clinical trial that evaluated the efficacy of administering \[18F\]FAPI-74 to detect fibroblast activation protein (FAP) expressing cells in participants diagnosed with gastrointestinal (GI) cancers.

Participant flow — Overall Study
Milestone[18F]FAPI-74 PET/CT
Started112
Completed95
Not completed17
Withdrew: Death1
Withdrew: Protocol deviation4
Withdrew: Withdrawal by participant5
Withdrew: Other (unspecified)7

Outcome measures

PrimaryPositive Predictive Value (PPV) of [18F]FAPI-74 PET Imaging Using Immunohistochemistry (IHC)

The positive or negative status according to \[18F\]FAPI-74 PET imaging was determined based on a prespecified cut-off value for each appropriate test as determined by the clinician. Positivity was evaluated using the following prespecified H-score thresholds: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only. The primary efficacy endpoint was the positive predictive value of \[18F\]FAPI-74 PET imaging, defined as the proportion of PET-positive results that were confirmed positive by IHC. PPV was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.

Time frame:
Day 1
Reported as:
Number · Proportion of participants
Positive Predictive Value (PPV) of [18F]FAPI-74 PET Imaging Using Immunohistochemistry (IHC)
Proportion of participants[18F]FAPI-74 PET/CT
IHC Cutoff: >501.0000 (1.000 to 1.000)
IHC Cutoff: >1000.7500 (0.632 to 0.868)
IHC Cutoff: >2000.2885 (0.165 to 0.412)
PrimarySensitivity of [18F]FAPI-74 PET Imaging to Detect FAP-Expressing Cells, Using IHC

Sensitivity was defined as the proportion of participants with IHC confirmed FAP-expressing cells who had a positive \[18F\]FAPI-74 PET result for the primary lesion. Sensitivity was calculated as A / (A + C), where A represents true positive findings and C represents false negative findings. Higher sensitivity indicates a greater ability of \[18F\]FAPI-74 PET to detect IHC confirmed FAP expression and a lower likelihood of false negative results, thereby reflecting the effectiveness of the imaging modality relative to the IHC reference standard. Sensitivity was presented overall for all IHC-positive results and separately using stricter IHC cut-off values categorized as: \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.

Time frame:
Day 1
Reported as:
Number · Proportion of participants
Sensitivity of [18F]FAPI-74 PET Imaging to Detect FAP-Expressing Cells, Using IHC
Proportion of participants[18F]FAPI-74 PET/CT
IHC Cutoff: >500.8966 (0.818 to 0.975)
IHC Cutoff: >1000.8667 (0.767 to 0.966)
IHC Cutoff: >2000.8824 (0.729 to 1.000)
Statistical analysis
  • [18F]FAPI-74 PET/CT · one-sample binomial proportion test · p = 0.0050 (The p-value for IHC cut-off \>50 was derived using a one-sample binomial proportion test with normal approximation, comparing the observed sensitivity against a prespecified performance goal of 0.75, using a one-sided significance level of 0.05.)
  • [18F]FAPI-74 PET/CT · one-sample binomial proportion test · p = 0.0354 (The p-value for IHC cut-off \>100 was derived using a one-sample binomial proportion test with normal approximation, comparing the observed sensitivity against a prespecified performance goal of 0.75, using a one-sided significance level of 0.05.)
  • [18F]FAPI-74 PET/CT · one-sample binomial proportion test · p = 0.1038 (The p-value for IHC cut-off \>200 was derived using a one-sample binomial proportion test with normal approximation, comparing the observed sensitivity against a prespecified performance goal of 0.75, using a one-sided significance level of 0.05.)
PrimarySpecificity of [18F]FAPI-74 PET Imaging to Detect Absence of FAP-Expressing Cells, Using IHC as Truth Standard

Specificity was defined as the proportion of participants without IHC-confirmed FAP-expressing cells who had a negative \[18F\]FAPI-74 PET result for the primary lesion. Specificity was calculated by comparing positive and negative \[18F\]FAPI-74 PET findings with the corresponding IHC results, using a single readable PET image matched to its reference IHC assessment. Specificity was calculated as D / (B + D), where B represents false-positive findings and D represents true-negative findings. PET results were compared with the corresponding IHC reference assessment using a single readable PET image per participant. Specificity was evaluated overall using IHC negativity defined as \> 50: Overall positive versus negative expression; \> 100: Moderate to high expression and \> 200: High expression only.

Time frame:
Day 1
Reported as:
Number · Proportion of participants
Specificity of [18F]FAPI-74 PET Imaging to Detect Absence of FAP-Expressing Cells, Using IHC as Truth Standard
Proportion of participants[18F]FAPI-74 PET/CT
IHC Cutoff: >501.0000 (1.000 to 1.000)
IHC Cutoff: >1000.1333 (0.000 to 0.305)
IHC Cutoff: >2000.1395 (0.036 to 0.243)
SecondaryPPV of [18F]FAPI-74 PET Images to Detect Cancer Cells Using Histopathology as Truth Standard

Positive Predictive Value (PPV) of \[18F\]FAPI-74 PET imaging in detecting presence of disease using histopathology as the truth standard. The PPV is defined as the probability that one is indeed positive for an outcome given that they test positive for the outcome and is calculated as: PPV = A/(A + B), where A represents true-positive findings and B represents false-positive findings (PET positive but histopathology negative). PPV was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.

Time frame:
Day 1
Reported as:
Number · Proportion of participants
PPV of [18F]FAPI-74 PET Images to Detect Cancer Cells Using Histopathology as Truth Standard
Proportion of participants[18F]FAPI-74 PET/CT
PPV of [18F]FAPI-74 PET Images to Detect Cancer Cells Using Histopathology as Truth Standard0.9423 (0.841 to 0.988)
SecondarySensitivity of [18F]FAPI-74 PET Imaging to Detect Cancers Cells, Using Histopathology as Truth Standard

Sensitivity was defined as the proportion of participants with histopathology-confirmed cancers cells who had a positive \[18F\]FAPI-74 PET result for the primary lesion. Sensitivity was calculated by comparing positive and negative \[18F\]FAPI-74 PET findings with the corresponding histopathology results, using a single readable PET image matched to its reference histopathology assessment. Sensitivity was calculated as A / (A + C), where A represents true-positive findings and C represents false-negative findings. Sensitivity was summarized using proportions along with two-sided 95% asymptotic normal confidence intervals.

Time frame:
Day 1
Reported as:
Number · Proportion of participants
Sensitivity of [18F]FAPI-74 PET Imaging to Detect Cancers Cells, Using Histopathology as Truth Standard
Proportion of participants[18F]FAPI-74 PET/CT
Sensitivity of [18F]FAPI-74 PET Imaging to Detect Cancers Cells, Using Histopathology as Truth Standard0.9074 (0.797 to 0.969)
SecondaryNumber of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) is any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with the trial intervention. A TEAE is defined as any untoward medical occurrence that begins or worsens in intensity or frequency after the initiation of a treatment (e.g., drug, device, or procedure) in a clinical study. A serious TEAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization.

Time frame:
From study intervention administration (Day 1) to 72 hours post-injection
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Participants[18F]FAPI-74 PET/CT
Any TEAE6
Any Serious TEAE2

Adverse events

Collected over From study intervention administration (Day 1) to 72 hours post-injection. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
[18F]FAPI-74 PET/CT1/109 (0.9%)2/109 (1.8%)6/109 (5.5%)
Most frequent serious events
Most frequent serious events
Event[18F]FAPI-74 PET/CT
Intestinal perforationGastrointestinal disorders1/109
PainGeneral disorders1/109
Pneumonia aspirationInfections and infestations1/109
Liver function test increasedInvestigations1/109
Most frequent other events
Most frequent other events
Event[18F]FAPI-74 PET/CT
NauseaGastrointestinal disorders2/109
Blood bilirubin increasedInvestigations1/109
Hepatic enzyme increasedInvestigations1/109
Liver function test increasedInvestigations1/109
Lymphocyte count decreasedInvestigations1/109
HeadacheNervous system disorders1/109

Baseline characteristics

Safety Analysis Set (SAS) comprises of all participants who received any amount of \[18F\]FAPI-74.

Age, Continuous
Age, Continuous(years)[18F]FAPI-74 PET/CT
Mean53.85 ± 10.82
Sex: Female, Male
Sex: Female, Male(Participants)[18F]FAPI-74 PET/CT
Female47
Male62
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)[18F]FAPI-74 PET/CT
Hispanic or Latino8
Not Hispanic or Latino95
Unknown or Not Reported6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)[18F]FAPI-74 PET/CT
American Indian or Alaska Native2
Asian16
Black or African American8
Native Hawaiian or Other Pacific Islander0
White66
Not Reported0
Unknown10
Multiracial0
Other7
08

Study locations

6 sites
  • University of California Los Angeles (UCLA) Health
    Los Angeles, California 90095, United States
  • Massachusetts general hospital
    Boston, Massachusetts 02114, United States
  • BAMF Health
    Grand Rapids, Michigan 49503, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55902, United States
  • Northwell Health
    Lake Success, New York 11042, United States
  • Memorial Sloan Kettering Cancer Center (MSKCC)
    New York, New York 10065, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jun 2025, 26 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 55 phase 2 interventional studies under Gastrointestinal Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2022
First posted
Dec 8, 2022
StartActual
Apr 28, 2023
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Results first posted
Oct 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 1, 2026
Enrollment
109→112
Oct 1, 2026
Primary outcomes
3 added, 1 removed
What changed in the outcomes
  • AddedPositive Predictive Value (PPV) of [18F]FAPI-74 PET Imaging Using Immunohistochemistry (IHC)Time frame: Day 1
  • AddedSensitivity of [18F]FAPI-74 PET Imaging to Detect FAP-Expressing Cells, Using IHCTime frame: Day 1
  • AddedSpecificity of [18F]FAPI-74 PET Imaging to Detect Absence of FAP-Expressing Cells, Using IHC as Truth StandardTime frame: Day 1
  • RemovedPositive predictive value will be determined on a per-lesion basis for all lesions with tissue available for FAP analysis.Time frame: Through study completion, 2 years
Oct 1, 2026
Documents
Secondary outcomes
3 added, 2 removed
What changed in the outcomes
  • AddedPPV of [18F]FAPI-74 PET Images to Detect Cancer Cells Using Histopathology as Truth StandardTime frame: Day 1
  • AddedSensitivity of [18F]FAPI-74 PET Imaging to Detect Cancers Cells, Using Histopathology as Truth StandardTime frame: Day 1
  • AddedNumber of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: From study intervention administration (Day 1) to 72 hours post-injection
  • RemovedPositive predictive value will be determined on a per-lesion basis for all lesions with tissue available for histopathology.Time frame: Through study completion, 2 years
  • RemovedFurther characterize the safety profile of [18F]FAPI-74 in subjects utilizing Common Terminology Criteria for Adverse Events (CTCAE v5)Time frame: Through study completion, 2 years
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Results posted
    Enrollment 109→112
    Primary outcomes 3 added, 1 removed
    What changed in the outcomes
    • AddedPositive Predictive Value (PPV) of [18F]FAPI-74 PET Imaging Using Immunohistochemistry (IHC)Time frame: Day 1
    • AddedSensitivity of [18F]FAPI-74 PET Imaging to Detect FAP-Expressing Cells, Using IHCTime frame: Day 1
    • AddedSpecificity of [18F]FAPI-74 PET Imaging to Detect Absence of FAP-Expressing Cells, Using IHC as Truth StandardTime frame: Day 1
    • RemovedPositive predictive value will be determined on a per-lesion basis for all lesions with tissue available for FAP analysis.Time frame: Through study completion, 2 years
    Secondary outcomes 3 added, 2 removed
    What changed in the outcomes
    • AddedPPV of [18F]FAPI-74 PET Images to Detect Cancer Cells Using Histopathology as Truth StandardTime frame: Day 1
    • AddedSensitivity of [18F]FAPI-74 PET Imaging to Detect Cancers Cells, Using Histopathology as Truth StandardTime frame: Day 1
    • AddedNumber of Participants Reporting Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: From study intervention administration (Day 1) to 72 hours post-injection
    • RemovedPositive predictive value will be determined on a per-lesion basis for all lesions with tissue available for histopathology.Time frame: Through study completion, 2 years
    • RemovedFurther characterize the safety profile of [18F]FAPI-74 in subjects utilizing Common Terminology Criteria for Adverse Events (CTCAE v5)Time frame: Through study completion, 2 years
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05641896
Lead sponsor
SOFIE
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Apr 28, 2023
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Results posted
Oct 1, 2026
Last update
Oct 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorine F 18 FAPI-74

Start the discussion